In an FGFR-insensitive KRAS-mutant lung cancer GEMM, neither the use of FGFR inhibitors alone nor in combination with anti-PD-1 monoclonal antibodies controlled tumors to improve survival in mice [23]. This evidence concerns the gene PDCD1 and lung cancer.